Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6ZS86

UPID:
GLPK5_HUMAN

ALTERNATIVE NAMES:
ATP:glycerol 3-phosphotransferase 5

ALTERNATIVE UPACC:
Q6ZS86; B2R9I2; D3DNG2; Q8N2A7; Q8N5E6

BACKGROUND:
The enzyme Putative glycerol kinase 5, with its alternative name ATP:glycerol 3-phosphotransferase 5, is integral to glycerol metabolism, facilitating the phosphorylation of glycerol to glycerol-3-phosphate. This process is essential for the synthesis of triglycerides and phospholipids, as well as for the regulation of glucose levels in the body.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Putative glycerol kinase 5 holds significant promise for identifying novel therapeutic approaches. Given its central role in metabolic processes, targeting this enzyme could lead to breakthroughs in treating diseases related to lipid metabolism and energy homeostasis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.